Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

ClinicalTrials.gov ID: NCT00277823

Public ClinicalTrials.gov record NCT00277823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.

Study identification

NCT ID: NCT00277823
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Enrollment: 480 participants

Conditions and interventions

Conditions

Major Depressive Disorder

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 31, 2006
Primary completion: Not listed
Completion: Dec 31, 2006
Last update posted: Dec 27, 2007

2006 – 2007

United States locations

U.S. sites: 25
U.S. states: 18
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Beverly Hills	California	90210	—
Not listed	Northridge	California	91324	—
Not listed	Farmington	Connecticut	06030	—
Not listed	Washington D.C.	District of Columbia	20037	—
Not listed	Miami	Florida	33173	—
Not listed	St. Petersburg	Florida	33702	—
Not listed	Marietta	Georgia	30060	—
Not listed	Smyrna	Georgia	30080	—
Not listed	Libertyville	Illinois	60048	—
Not listed	New Orleans	Louisiana	70115	—
Not listed	Farmington Hills	Michigan	48336	—
Not listed	Clementon	New Jersey	08021	—
Not listed	Moorestown	New Jersey	08057	—
Not listed	New York	New York	10021	—
Not listed	New York	New York	10024	—
Not listed	Dayton	Ohio	45408	—
Not listed	Toledo	Ohio	43623	—
Not listed	Oklahoma City	Oklahoma	73103	—
Not listed	Portland	Oregon	97210	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Charleston	South Carolina	29407	—
Not listed	Columbia	South Carolina	29201	—
Not listed	Salt Lake City	Utah	84107	—
Not listed	Seattle	Washington	—	—
Not listed	Brown Deer	Wisconsin	53223	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00277823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 27, 2007 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00277823 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →